Difficulty: Medium
Average Score: 67%
Practice
A 33-year-old female diagnosed with bipolar I disorder has been functioning well on lithium for 11 months. At her most recent checkup, the psychiatric nurse practitioner states, 'You are ready to enter the maintenance therapy stage, so at this time I am going to adjust your dosage by prescribing:'
Correct answer
C
Rationale
Bipolar I disorder is a chronic condition requiring long-term management, and lithium remains a first-line mood stabilizer for both acute episodes and maintenance therapy. The key principle in maintenance therapy is to prevent recurrence of manic or depressive episodes while minimizing side effects and maintaining the patient's quality of life. After 11 months of stability, the patient has likely achieved therapeutic lithium levels (typically 0.6ÔÇô1.2 mEq/L for acute treatment). In the maintenance phase, the goal shifts to sustaining stability at the *lowest effective dose*, often reducing the serum level to 0.6ÔÇô0.8 mEq/L. This adjustment decreases the risk of long-term adverse effects (e.g., renal toxicity, thyroid dysfunction, or cognitive dulling) while still providing prophylaxis against relapse. Thus, **a lower dosage (C)** is correct because it aligns with evidence-based practice for maintenance therapyÔÇöbalancing efficacy with safety.
**Why other choices are incorrect:**
- **A higher dosage (A):** Increasing the dose is unnecessary for a patient already stable on lithium. Higher doses raise serum levels, increasing the risk of toxicity without proven added benefit in maintenance. Elevated levels could lead to adverse effects (e.g., tremors, polyuria, or electrolyte imbalances), undermining adherence and long-term outcomes.
- **Once-weekly dosing (B):** Lithium has a narrow therapeutic index and requires consistent dosing to maintain stable serum levels. Its half-life (12ÔÇô27 hours) necessitates *daily* administration to avoid fluctuations that could trigger breakthrough symptoms or toxicity. Weekly dosing would cause erratic absorption, risking subtherapeutic levels (and relapse) or toxic peaks.
- **A different drug (D):** Switching medications is not indicated for a patient responding well to lithium. Lithium has unique neuroprotective and anti-suicidal properties in bipolar disorder, and abrupt changes could destabilize the patient. Alternatives (e.g., valproate or lamotrigine) are reserved for intolerance or inadequate response, neither of which is described here.
The rationale hinges on the *maintenance phase objective*: optimizing long-term outcomes by reducing dosage while monitoring for stability. This approach reflects clinical guidelines emphasizing minimal effective dosing to mitigate risks without compromising relapse prevention.
**Why other choices are incorrect:**
- **A higher dosage (A):** Increasing the dose is unnecessary for a patient already stable on lithium. Higher doses raise serum levels, increasing the risk of toxicity without proven added benefit in maintenance. Elevated levels could lead to adverse effects (e.g., tremors, polyuria, or electrolyte imbalances), undermining adherence and long-term outcomes.
- **Once-weekly dosing (B):** Lithium has a narrow therapeutic index and requires consistent dosing to maintain stable serum levels. Its half-life (12ÔÇô27 hours) necessitates *daily* administration to avoid fluctuations that could trigger breakthrough symptoms or toxicity. Weekly dosing would cause erratic absorption, risking subtherapeutic levels (and relapse) or toxic peaks.
- **A different drug (D):** Switching medications is not indicated for a patient responding well to lithium. Lithium has unique neuroprotective and anti-suicidal properties in bipolar disorder, and abrupt changes could destabilize the patient. Alternatives (e.g., valproate or lamotrigine) are reserved for intolerance or inadequate response, neither of which is described here.
The rationale hinges on the *maintenance phase objective*: optimizing long-term outcomes by reducing dosage while monitoring for stability. This approach reflects clinical guidelines emphasizing minimal effective dosing to mitigate risks without compromising relapse prevention.